Please login to the form below

Scottish Medicines Consortium

This page shows the latest Scottish Medicines Consortium news and features for those working in and with pharma, biotech and healthcare.

Merck and Pfizer set to win NICE backing for Bavencio

The pharma giants are expecting final guidance from NICE within the next coming weeks, and a decision by the Scottish Medicines Consortium (SMC) is also expected.

Latest news

NICE reverses its rejection of Eisai’s Lenvima

This particular subset of patients in Scotland and Wales can already access Eisai’s medicine due to approvals from the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy. ... The positive recommendation comes three years after the
NICE backs Roche’s Gazyvaro after initial rejection

The Scottish Medicines Consortium (SMC) turned down Gazyvaro as a first-line option with chemotherapy last month.
NICE finally starts review of Biogen’s Spinraza for SMA

Biogen notes that Spinraza is reimbursed in Italy and Sweden, with ongoing negotiations taking place across Europe including Scotland where it is under active appraisal by the Scottish Medicines Consortium (SMC).
Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

an extra line of therapy to patients and doctors across the UK.”The Scottish Medicines Consortium backed NHS funding for fourth-line use of the drug last year.
SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Janssen has persuaded the Scottish Medicines Consortium (SMC) to reverse its initial ruling on Darzalex (daratumumab), after the pharma group offered to cut the first-in-class drug’s price through ... The drug was previously rejected by the National

More from news
Approximately 4 fully matching, plus 85 partially matching documents found.

Latest Intelligence

The reality of real-world evidence

Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Director – Medical Education – Oxford: Negotiable

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Account Manager / Account Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Programme Executive: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Scientific Director: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Subscribe to our email news alerts

PMHub

Add my company

Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...